Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)

NCT07201922 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07201922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07201922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Recruiting
Start date
February 10, 2026
Completion date
May 23, 2029
Enrollment
80 (estimated)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

familial pulmonary fibrosis, interstitial lung abnormalities, interstitial lung diseases